Biotech Nuvalent unveiled updates on two experimental cancer medicines over the weekend. Analysts say each could be the best ...
Charles Zhu, an analyst from LifeSci Capital, maintained the Buy rating on Nuvalent (NUVL – Research Report). The associated price target ...
Zacks.com on MSN3d
Nuvalent Stock Moves Up 20% in a Week: What's Driving the Rally?Shares of Nuvalent NUVL have soared nearly 20% in the past week owing to encouraging updates on its two investigational ...
Shares of Nuvalent NUVL have soared nearly 20% in the past week owing to encouraging updates on its two investigational therapies. Both therapies target previously treated non-small cell lung ...
Nuvalent achieved positive data from the phase 1/2 ALKOVE-1 study using NVL-655 for the treatment of patients with ALK-mutant ...
Nuvalent, Inc. (NUVL), a company focused on cancer treatment, announced on Monday that it has commenced an underwritten public ...
Nuvalent shows promise with strong clinical data for zidesamtinib and NVL-655 in treating ROS1- and ALK-positive NSCLC. Read ...
We recently compiled a list of the 10 Largest Biotech Hedge Funds and Their Top Stock Picks. In this article, we are going to ...
Nuvalent shares are trading lower by 6.2% during Tuesday's session. The company priced a $500 million public offering of 5 million shares at $100 each. Nuvalent Inc NUVL shares are trading lower ...
We recently compiled a list of the 10 Worst Cancer Stocks To Buy Now According to Short Sellers. In this article, we are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback